MedTrace Logo

DRonabinol Treatment of OSA

NCT06477952 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-09-12

No results posted yet for this study

Summary

This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.

Conditions

Interventions

DRUG

Dronabinol

Open label Dronabinol treatment for two weeks.

Sponsors & Collaborators

  • University of Illinois at Chicago

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Bharati Prasad, MD · Jesse Brown VA Medical Center, Chicago, IL

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-25
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477952 on ClinicalTrials.gov